{"url_path":"/sec/lab/8-k/2026-06-05/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-05","source_url":"https://www.sec.gov/Archives/edgar/data/1162194/0001193125-26-259877-index.html","accession_number":"0001193125-26-259877","cik":"0001162194","ticker":"LAB","issuer_name":"STANDARD BIOTOOLS INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1162194/0001193125-26-259877-index.html","primary_entity_key":"0001162194","primary_entity_name":"STANDARD BIOTOOLS INC."},"word_count":173,"has_tables":true,"body_markdown":"Item 8.01 Other Events.\n\nOn June 5, 2026, Standard BioTools Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it has regained compliance with Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”).\n\nAs previously reported, on April 20, 2026, the Company received written notice from the Staff of Nasdaq notifying the Company that, because the closing bid price for the Company’s common stock, par value $0.001 per share, had fallen below $1.00 per share for 30 consecutive business days, the Company no longer met the minimum bid price requirement for continued inclusion on The Nasdaq Global Select Market pursuant to the Bid Price Requirement. This matter is now closed.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nDate:\n \nJune 5, 2026\n\nSTANDARD BIOTOOLS INC.\n\nBy:\n \n\n/s/ Alex Kim\n\nName:\n \nAlex Kim\n\nTitle:\n \nChief Financial Officer"}